Friend John E. Ii - Net Worth and Insider Trading

Friend John E. Ii Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Friend John E. Ii owns 1 companies in total, including Cellectar Biosciences Inc (CLRB) .

Click here to see the complete history of Friend John E. Ii’s form 4 insider trades.

Insider Ownership Summary of Friend John E. Ii

Ticker Comapny Transaction Date Type of Owner
CLRB Cellectar Biosciences Inc 2020-07-01 VP & Chief Medical Officer

Friend John E. Ii Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Friend John E. Ii Ownership Network

Ownership Network List of Friend John E. Ii

No Data

Ownership Network Relation of Friend John E. Ii


Friend John E. Ii Owned Company Details

What does Cellectar Biosciences Inc do?

Who are the key executives at Cellectar Biosciences Inc?

Friend John E. Ii is the VP & Chief Medical Officer of Cellectar Biosciences Inc. Other key executives at Cellectar Biosciences Inc include Senior Vice President & Medical Andrei Shustov , Chief Commercial Officer Darrell Shane Lea , and Chief Financial Officer Chad J Kolean .

Cellectar Biosciences Inc (CLRB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cellectar Biosciences Inc (CLRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cellectar Biosciences Inc (CLRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cellectar Biosciences Inc (CLRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cellectar Biosciences Inc Insider Transactions

No Available Data

Friend John E. Ii Mailing Address

Above is the net worth, insider trading, and ownership report for Friend John E. Ii. You might contact Friend John E. Ii via mailing address: 26 Orchard Lane, Colt Neck Nj 07722.

Discussions on Friend John E. Ii

No discussions yet.